S
inoatrial node (SAN) disease is a highly prevalent but poorly understood form of cardiovascular disease that occurs in a number of conditions including hypertension, hypertrophy, and heart failure (1) (2) (3) (4) . Arrhythmias associated with SAN dysfunction account for approximately 50% of sudden deaths in the hospital in heart failure patients (2, 5) . A common theme in these prevalent forms of cardiovascular disease is a pathological elevation in angiotensin II (Ang II) and enhanced Ang II signaling (6, 7) . SAN disease in hypertension and heart failure is Under normal conditions, the heart beat is initiated in the SAN due to the ability of this specialized region of the heart to generate spontaneous APs characterized by the presence of a diastolic depolarization (DD) (9, 10) . The DD is produced by a number of underlying ionic mechanisms including the hyperpolarizationactivated current (I f ), T-type and L-type Ca 2þ currents (I Ca,T and I Ca,L , respectively), a Na þ -Ca 2þ exchange current (I NCX ) driven by sarcoplasmic reticulum Ca 2þ release, and repolarizing K þ currents (9, 11) . Alterations in the activity and coordination of these currents can compromise SAN pacemaker activity. Pacemaker activity in the heart is also importantly affected by the amount of fibrosis in the SAN, and enhanced fibrosis can impair normal SAN function (6, 12) . Natriuretic peptide(s) (NP) are a family of cardioprotective hormones with a number of effects in the cardiovascular system that are mediated by specific NP receptors called NPR-A, -B, and -C (13, 14) .
Among this family, NPR-C remains the least understood. We have demonstrated that NPs have potent effects on cardiac electrophysiology, including in the SAN, and that some of these effects can be mediated by NPR-C (14) (15) (16) (17) (18) . Furthermore, we have recently shown that NPR-C knockout (NPR-C À/À ) mice develop SAN dysfunction in association with enhanced fibrosis (19) . These findings suggest that NPR-C plays an integral role in maintaining normal SAN structure and function and that it could be a novel therapeutic target; however, the role of NPR-C 
METHODS
An expanded methods and materials section can be found in the Supplemental Material.
ANIMALS AND SURGICAL INTERVENTIONS. This study used male wild-type and NPR-C À/À mice between 10 and 15 weeks of age. NPR-C À/À mice were initially obtained from the Jackson Laboratory (strain B6;C-Npr3lgj/J, Bar Harbor, Maine) and backcrossed into the C57Bl/6 line as we previously reported (15, 19, 20 HIGH-RESOLUTION OPTICAL MAPPING. To study activation patterns and electrical conduction in the right atrial posterior wall, high-resolution optical mapping was performed in isolated atrial preparations, using methods we have described in detail previously (17, 19, 24, 25) . Atrial preparations were immobilized using blebbistatin (1 mM) (26 Single pacemaker myocytes from the SAN were isolated using procedures we have described previously (15, 19) . Spontaneous APs were recorded using the perforated patch clamp technique in current clamp mode, while I f and I Ca,L were recorded in the whole-cell configuration in voltage clamp mode.
Solutions and protocols for these measurements are described in detail in the Supplemental Material.
QUANTITATIVE POLYMERASE CHAIN REACTION.
Quantitative gene expression in the SAN (or right and left atria) was performed using established techniques we have described previously (15, 25) . Genes of interest that were measured include Npr1 (encodes
HCN1, HCN2, HCN4, SCN5a (encodes NaV1.5), GJC1
(encodes Cx45), and GJA1 (encodes Cx43 Figure S1 ). These data demonstrated that Ang II treatment increased (p < 0.001) SBP to very similar extents in wild-type and NPR-C À/À mice, such that there were no differences (p ¼ 0.115) in the extent of hypertension between genotypes. There were also no differences (p ¼ 1.000) in systolic pressure between wild-type and NPR-C À/À mice at baseline, as we have shown previously (19) . As expected, saline treatment had no effect (p ¼ 1.000) on systolic pressure. Mackasey et al.
that were shifted inferiorly compared with those in saline-treated hearts.
We quantified cycle length and local conduction velocity (CV) within the right atrial posterior wall, using our previously established approaches (19, 25) .
These data demonstrated that cycle length ( Figure wild-type controls, whereas Ang II treatment in NPR-C À/À mice resulted in the longest (p ¼ 0.048) cycle lengths. As expected, CVs in this region of the heart were relatively low (i.e., <10 cm/s) ( Figure 2D ) (19, 24) . Next, we used echocardiography to determine the effects of cANF co-treatment on cardiac structure and function. M-mode images (Supplemental Figure S10) and summary data (Supplemental Table S3) were not different from those in saline controls ( Figures 5B and 5C ).
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Role of NPR-C in Sinoatrial Node Disease Consistent with these effects on AP morphology, cANF also dose-dependently prevented the reduction in I f elicited by Ang II in SAN myocytes ( Figure 7D ). Figure S11 ).
Finally, we assessed the effects of cANF cotreatment on fibrosis in the SAN by using picrosirius red staining and HCN4 immunostaining (Figure 8 ).
These data demonstrate that the lower dose of cANF In previous studies (15, 19) and the present one, we have shown that NPR-C is the most highly expressed NPR in the heart, including in the SAN. Our present study also demonstrates that chronic Ang II treatment Similarly, SAN disease has been described in canine studies of heart failure induced by atrial tachypacing (51, 52 (53) . Similarly, endurance athletes exhibit bradycardia and a higher incidence of SAN disease in association with reductions in the expression of HCN4 and I f density (54) .
We also examined other potential mediators of electrical dysfunction by measuring the mRNA expression levels of SCN5a, GJC1, and GJA1. SCN5a has been shown to be present in the periphery of the SAN and to play a role in electrical conduction from the SAN to the atrial myocardium (32, 55) . We observed no changes in SCN5a expression in the SAN following Ang II treatment. Cx45 is a critical connexin in the SAN where it facilitates cell-to-cell communication (33) ; however, we observed no differences in Cx45 expression after Ang II treatment.
Cx43 is primarily located in the atria and is mostly absent in the SAN, although strands of Cx43-positive tissue have been found to extend into the SAN (28, 33, 56) . Furthermore, numerous studies have
shown that Cx43 mRNA can be detected in the SAN (34, 35, 57) . Accordingly, we measured Cx43 expression and found it was modestly reduced after Ang II treatment. Because the SAN is considered to be primarily a Cx43-negative region and the reduction we measured was very small, it is unlikely that a downregulation of Cx43 contributed substantially to the effects of Ang II on electrical conduction in the SAN.
Nevertheless, we measured mRNA levels only for SCN5a, Cx45, and Cx43, and these targets could be altered in ways that do not involve changes in gene expression, which could be investigated in future studies.
In addition to preventing SAN fibrosis, we found As mentioned, the impairments in electrical conduction in the SAN occurred in association with shifts in the location of the leading pacemaker site.
The SAN is a heterogeneous structure (56) , and it is conceivable that differences in expression levels of ion channels such as HCN4 in the superior and inferior pacemaker locations could contribute the alterations in function we observed. Furthermore, studies in the human and canine heart have demonstrated the existence of distinct SAN conduction pathways that can be accessed depending on location of leading pacemaker site (10, 58, 59) , and this may further contribute to changes in SAN conduction. Although a study in human heart showed that HCN4 expression levels were similar in the head, the center, and the tail of the SAN (60), it is possible that there may be alterations in the diseased heart. Thus, it will be useful to explore the effects of Ang II on regional expression of HCN4 and possibly other channels (e.g., HCNs, calcium channels) in different parts of the SAN in future studies. STUDY LIMITATIONS. The present study focused on SAN dysfunction following Ang II treatment in mice.
In addition, echocardiographic data demonstrated that Ang II treatment caused concentric ventricular hypertrophy in wild-type mice and ventricular dilation and heart failure in NPR-C À/À mice. These findings suggest that NPR-C might have affected electrical or structural remodeling in the ventricles as well.
Similarly, Ang II treatment has been shown to cause atrial fibrillation (65, 66) , and it is possible that NPR-C affects atrial remodeling in addition to its effects in the SAN. Although our study demonstrates important effects of NPR-C in the SAN, it is also important to recognize that global ablation of NPR-C and systemic application of cANF can also have noncardiac effects.
Although these were not the foci of our study, it is conceivable that treatment with NPs could have effects on the vasculature, kidneys, and other systems that may further affect disease progression. These areas will be important for additional studies. Our study was conducted in mouse models, which was essential for identifying new roles for NPR-C using knockout mice. It will be important to validate these findings in large animal models and ultimately in human patients. how to translate these findings to human patients.
